Variants of renal osteodystrophy


Citar

Texto integral

Resumo

Clinical and pathogenetic variants of renal osteodytsrophy and approaches to treatment are discussed

Bibliografia

  1. National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am. J. Kidney Dis. 2003 (suppl. 3); 42: S1-S202
  2. Нефрология: национальное руководство / под ред. Н.А. Мухина. М.: ГЕОТАР-Медиа. 2009; 616-628
  3. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D. Нефрол. диал. 2004; 2(6): 116-127
  4. Yajima A., Inaba M., Tominaga Y., Ito A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 2008; 74: 775-781.
  5. KDIGO. Clinical Practice for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl): 113-120
  6. Brossard J.H., Lepage R., Cardinal H., Roy L., Rousseau L., Dorais C., D'Amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin. Chem. 2000; 46: 697-703
  7. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am. J. Kidney Dis. 2000; 35: 1226-1237
  8. Рожинская Л.Я. Вторичный гиперпаратиреоз и почечный остеопатии при хронической почечной недостаточности. Нефрол. диал. 2000; 4(2): 241-247
  9. Шило В.Ю. Гиперпаратиреоз и кальцимиметики. Нефрол. диал. 2009; 3(11): 144-233
  10. Земченков А.Ю., Герасимчук Р.П. Активаторы рецепторов витамина D и сосудистая кальцификация (обзор литературы). Нефрол. диал. 2009; 4(11): 276-292
  11. Danese M.D., Belozeroff V., Smirnakis K., Rothman K.J. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1423-1429
  12. Sprague S.M., Moe S.M. Clinical manifestations and pathogenesis of dialysis-related amyloidosis. Semin. Dial. 1996; 9: 360-369
  13. Gal R., Korzets A., Schwartz A., Rath-Wolfson L., Gafter U. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis populations. Arch. Pathol. Lab. Med. 1994; 118: 718-721
  14. Portale A.A. Blood calcium, phosphorus, and magnesium, in Favus M.J. (ed): Primer on the Metabilic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, PA, Lippincott, Williams &Wilkins. 1999; 115-118
  15. Stehman-Breen C.O., Sherrard D.J., Alem A.M., Gillen D.L., Heckbert S.R., Wong C.S., Ball A., Weiss N.S. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58: 2200-2205
  16. Coco M., Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am. J. Kidney Dis. 2000; 36: 1115-1121
  17. Alem A.M., Sherrard D.J., Gillen D.L., Weiss N.S., Beresford S.A., Heckbert S.R., Wong C., Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal dis. Kidney Int. 2000; 58: 396-399
  18. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрол. диал. 2002; 2(4):113-117
  19. Yamazaki Y. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008; 23: 1509-1518
  20. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperperathyroidism in a haemodialysis patient. Nephrol. Dial. Transplant. Plus. 2008; 1: 148-150
  21. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. Curr. Vasc. Pharmacol. 2008; 6: 148-153
  22. Cozzolino M., Brandenburg V. Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin. Nephrol. 2009; 71(6): 593-601
  23. Lund R.J., Andress D.L., Amdahl M. et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol. 2010; 31(2): 165-170
  24. Schumock G.T., Walton S.M., Lee T.A. et al. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin Pract. 2011; 117(2): c151-c159
  25. Nuijten M., Andress D.L., Marx S.E. et al. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig. 2010; 30(8): 545-557 26. de Zeeuw D., Agarwal R., Amdahl M. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376: 1543-1551
  26. Ohashi K., Hara M., Kawai R., Ogura Y., Honda K., Nihei H., Mimura N. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column. Kidney Int. 1992; 41: 1646-1652
  27. Jadoul M., Malghem J., Vande Berg B., van Ypersele de Strihou C. Ultasonographic datertion of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol. Dial. Transplant. 1993; 8: 1104-1109
  28. Zingraff J., Noel L.H., Bardin T., Kuntz D., Dubost C., Drueke T. Beta 2-microglobulin amyloidosis: A sternoclavicular joint biopsy study in hemodialysis patients. Clin. Nephrol. 1990; 33: 94-97
  29. Fliser D., Kollerits B., Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600-2608
  30. Franceschi R.T., Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J. Cell. Biochem. 2003; 88: 446-454
  31. Fukagawa M., Yumita S., Akizawa T. et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol. Dial. Transplant. 2008; 23: 328-335
  32. Cravaca F., Fernandez M.A., Ruiz-Calero R., Cubero J., Aparicio A., Jimenez F., Garcia M.C. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol. Dial. Transplant. 1998; 13: 2605-2611
  33. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am. J. Kidney Dis. 1999; 34: 875-883
  34. Torres A., Rodrigues A.P., Cocepcion M.T., Garcia S., Rufino M., Martin B., Perez L., Machado M., de Bonis E., Losada M., Hernandez D., Lorenzo V. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentration. Nephrol. Dial. Transplant. 1998; 13 (suppl. 3): 94-97
  35. Dumoulin G., Hory B., Nguyen N.U., Henriet M.T., Bresson C., Regnard J., Saint-Hillier Y. Lack of evidence that cyclosporine treatment impairs calcium-phospharus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplant. 1995; 59: 1690-1694
  36. Lukert B.P., Raisz L.G. Glucocorticoid-indused osteoporosis: Pathogenesis and management. Ann. Inrern. Med. 1990; 112: 352-364
  37. Dempster D.W. Bone histomorhometry in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 1989; 4: 137-141
  38. Grotz W.H., Mundinger F.A., Rasenack J., Speidel L., Olschewski M., Exner V.M., Schollmeyer P.J. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol. Dial. Transplant. 1995; 10: 2096-2100
  39. Cueto-Manzano A.M., Konel S., Hutchison A.J., Crowley V., France M.W., Freemont A.J., Adams J.E., Mawer B., Gokal R. Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int. 1999; 55: 2021-2029
  40. Aroldi A., Tarantino A., Montagnino G., Cesana B., Cocucci C., Ponticelli. Effect of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplant. 1997; 63: 380-386
  41. Ficat R.P. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment . J. Bone Joint Surg. Br. 1985; 67: 3-9
  42. Hasselblad V., Hedges L.V. Meta-analysis of screening and diagnostic tests. Psycho. Bull. 1995; 117: 167-178
  43. Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H., Blair H.C. bisphosphonates directly inhibit the bone resorption activity of isolated avain osteoclasts in vitro. J. Clin. Invest. 1990; 85: 456-461
  44. Grotz W.H., Rump L.C., Niessen A., Schollmeyer P.J. Traatment of osteopenia and osteoporosis after kidney transplantation. Transplant. 1998; 66: 1004-1008
  45. Grotz W.H., Rump L.C., Niessen A., Schmidt-Gayk H., Reichelt A., Kirste G., Olschewski M., Scholl-Meyer P.J. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplant. 1998; 66: 1004-1008

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies